Epigenetic Mechanisms of Glioblastoma

PEIYAO LI1,2 • MINGHUA WU1,2

1The Key Laboratory of Carcinogenesis of the Chinese Ministry of Health, Cancer Research Institute, Central South University, Changsha, Hunan, China; 2The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, China

Author for correspondence: Minghua Wu, The Key Laboratory of Carcinogenesis of the Chinese Ministry of Health, Cancer Research Institute, Central South University, Changsha, Hunan 410008, China.
E-mail: wuminghua554@aliyun.com
Doi: http://dx.doi.org/10.15586/codon.glioblastoma.2017.ch3

Abstract: Aberrant DNA methylation is a common event in the genesis and progression of tumors. The application of next-generation sequencing enables the identification and mapping of DNA methylation and its derivatives, 5fC and 5hmC, to base-pair resolution. This chapter describes nine novel hypermethylation genes and six hypomethylation genes, identified by constructing a DNA methylation profile, in glioblastoma. Abnormal promoter methylation and histone modifications were associated with differential expression of miRNAs in glioblastoma: miR-185 reversed global DNA methylation and the methylation level of the hypermethylation genes by targeting DNMT; and miR-101 regulated histone methylation of hypomethylation genes by targeting EED, EZH2, and DNMT3A. The long noncoding RNA CASC2c directly bound to miR-101 via microRNA response elements, and there was a reciprocal repression between CASC2c and miR-101. Despite being competitors they both led to the overexpression of their target hypomethylation genes CPEB1, PRDM16, and LMO3.
Taken together, glioblastoma is a complicated pathological process with deregulated methylation and histone modifications. Focal differentially methylated region and differentially methylated site studies will be helpful for the identification of regulatory elements of transcription. Studies of intragenic and distant intergenic alterations in DNA methylation will help elucidate the nature of epigenetic deregulation in glioblastoma.

Key words: Glioblastoma; Histone modification; lncRNA; Methylation; miRNA

Introduction

Aberrant DNA methylation patterns have been shown to be common events in the genesis and progression of tumors (1). In cancer cells, a general decline in the level of methylated cytosine (genomic hypomethylation) is accompanied by local locus-specific hypermethylation (2, 3). Genomic hypomethylation contributes to genetic instability and proto-oncogene hypomethylation, which is responsible for their stronger expression (4). In addition, functional silencing of tumor-associated genes is usually associated with local promoter hypermethylation (5). Thus, alterations in tumor cell DNA methylation patterns contribute to abnormal gene expression and malignant phenotypes. Glioblastoma multiforme is the most common and aggressive primary central nervous system tumor in adults. Abnormal DNA methylation is responsible for glioblastoma genesis, development, and malignancy progression (6). Promoter hypermethylation and epigenetic silencing of the MGMT gene have been widely described in glioma (7–9). Several genes that are involved in key cellular functions such as the cell cycle (10), tumor suppression (11–15), DNA repair (16, 17), tumor invasion (18), and apoptosis (19) have been shown to be silenced in association with promoter hypermethylation in malignant glioblastoma. Despite these important findings, aberrant DNA methylation on genome-wide scale is still not fully understood in glioblastoma. This chapter describes nine novel hypermethylation genes and six hypomethylation genes, identified by constructing a genome-wide DNA methylation profile, in glioblastoma.

Methylomes of Glioblastoma

DNA METHYLATION PROFILE IN GLIOBLASTOMA

MeDIP-chip was used to investigate the whole-genome differential methylation patterns between glioblastoma and nontumor brain samples (20). A total of 104 hypomethylated and 524 hypermethylated regions were identified in glioblastoma. Of these, 70 hypomethylated and 361 hypermethylated regions were CpG islands (Figure 1A). Thirty hypomethylated and 199 hypermethylated regions were mapped to the unannotated gene regions (Figure 1B). Meanwhile, 74 hypomethylation and 325 hypermethylation regions were mapped to
annotated gene regions comprising the promoter region, intragenic region, and the regions downstream. Furthermore, 81.1% (60 of 74) of hypomethylated and 66.5% (216 of 325) of hypermethylated regions mapped to the promoter regions of annotated genes (Figure 1C). Twenty-seven hypomethylated and 53 hypermethylated regions mapped to CpG islands as well as the promoters of known genes (Figure 1D). Thus, a number of new differential methylation regions (DMRs) were shown to exist in unannotated genomic regions as well as the promoter regions, intragenic regions, and regions downstream of known genes in glioblastoma. The promoter hypermethylated genes exist predominately on chromosomes 1, 2, 3, 17, and x, while the promoter hypomethylated genes were mainly distributed on chromosomes 1, 11, 16, 19, 20, and 22 (Figure 1D). The functional and pathway analyses of these differential promoter methylated genes were performed by the DAVID bioinformatics tools. Most of the differential promoter methylated genes belonged to signaling networks that played critical roles in regulation of transcription, neurological process, ion transport, cell adhesion, apoptosis, and regulation of tumor development (Tables 1 and 2). Promoter hypermethylated genes that were correlated to

![Figure 1](image)

**Figure 1** Genome-wide analysis of DMRs in primary glioblastoma. (A) DMRs (differentially methylated regions) are correlated with or without genes. Most identified DMRs are mapped to gene promoters. (B) Distribution of DMRs is correlated with genes. Most identified DMRs are mapped to both gene promoters and CpG islands. (D) Chromosomal distribution of 60 promoter hypomethylated genes and 216 promoter hypermethylated genes (Zuping Zhang, Guiyuan Li. Study on epigenetic mechanisms of glioma. Doctoral thesis, Central South University, 2009; 12).
| Gene Ontology Analysis                                                                 | Promoter Hypermethylation Genes                                                                 |
|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Cell communication and intracellular signal transduction                               | 22 Genes: ANKDD1A, OPN1MW, PKP1, PCDHB13, PI4KA, HSH2D, KNDC1, KCNMB3SST, DIRAS3, PTAFR, KCNN3, OR10Q1, CD81, ABRA, CASP9, FYN, MBP, OR10H5, RCVRN, GPR31, KCNMB2, TDGF1, |
| Neurological system process, and synaptic and nerve impulse transmission                | 20 Genes: SIX3, PI4KA, RCVRN, PCDHB13, OR10H5, MBP, KCNMB2, KCNMB3, CLN3, MPZ, S100P, TRPV1, DLGAP2, PROM1, FYN, SYPL1, SST, GAD1KCNN3, OR10Q1, HTR1D |
| Negative regulation of biological process, metabolic process, cellular process, and transcription activity | 16 Genes: PAIP2, TDGF1, RASSF1, DEDD2, GRLF1, SALL4, RASSF2, TMSB4Y, CFTR, CLN3, GDNF, SIX3, DKK4, SST, ST18, B4GALNT2 |
| Chemical homeostasis, homeostatic process, ion homeostasis, regulation of pH, and biological quality | 13 Genes: KCNMB3, CCKAR, CLN3, MPZ, TRPV1, CYP11B2, RPH3AL, DNAJC16, DEDD2, MB KCNMB2, MBP, EDNRB |
| Brain development, neurons generation, and migration                                    | 9 Genes: FYN, SIX3, CFTR, NNAT, CCKAR, ROBO2, GRLF1, GDNF, LRRC4                             |
| Cell and biological adhesion, homophilic cell adhesion, and Cadherin                   | 13 Genes: SDK1, FBLN7, PCDHB13, CLDN18, PKP1, CD300A, ROBO2, PCDHA12, PARVB, FGF6, FLRT1FERMT3, PCDHA8, PCDHA13 |
| Ion transport, calcium channel, cation channel activity, gated channel activity, and ion transmembrane transporter activity | 10 Genes: KCNMB3, TRPV1, FYN, CACNG7, KCNN3, TRPV3, CACNG1, SLC5A11, KCNK10, KCNMB2 |
| Migration and motility of cell, localization of cell, cellular morphogenesis during differentiation, and cellular structure morphogenesis | 9 Genes: S100P, TDGF1, EDNRB, SST, FYN, CCKAR, GDNF, ROBO2, CFTR |
| Actin binding and cytoskeletal protein binding                                         | 8 Genes: TMSB4Y, PDE4DIP, FYN, PARVB, ABRA, C14 or f49, RPH3AL, PHACTR3                     |
| Apoptosis induction by extracellular signals                                           | 2 Genes: SST, DEDD2                                                                         |
| Neuroactive ligand–receptor interaction                                                | 6 Genes: EDNRB, PTAFR, HTR1D GH2, SST, CCKAR, TRPV1                                         |

| KEGG Pathway Analysis                                                                 | Promoter Hypermethylation Genes                                                                 |
|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| MAPK signaling pathway                                                               | 4 Genes: MAP2K3, CACNG7, FGF6, CACNG1                                                     |
| WNT signaling pathway                                                                | 1 Gene: DKK4                                                                               |
| JAK-STAT signaling pathway                                                           | 1 Gene: GH2                                                                               |
human tumor development included EDNRB, ARHI, FYN, GIPC2, GDNF, RASSF1, RASSF2, and ARHI (21–25).

**NINE NOVEL HYPERMETHYLATION GENES IN GliOBlastoma**

Sequenom MassARRAY platform quantitative analysis confirmed that LRRC4, ANKDD1A, GAD1, SIX3, SST, PHOX2B, PCDHA8, HIST1H3E, and PCDHA13 were the nine novel promoter hypermethylation genes in glioblastoma (Figure 2B). LRRC4 (GeneBank: AF196976) is not only a brain-specific gene but also a novel candidate for tumor suppression. Methylation-mediated inactivation of LRRC4, SIX3, and ANKDD1A has been verified as a frequent and glioblastoma-specific

| Table 2: Gene Ontology and KEGG Pathway Enrichment Analysis of Promoter Hypomethylation Genes Identified by MeDIP-Chip (Zuping Zhang, Doctoral thesis. Central South University, 2009) |
| --- |
| **Genes** | **Gene Ontology Analysis** |
| LRRC4, ANKDD1A, GAD1, SIX3, SST, PHOX2B, PCDHA8, HIST1H3E, and PCDHA13 were the nine novel promoter hypermethylation genes in glioblastoma (Figure 2B). LRRC4 (GeneBank: AF196976) is not only a brain-specific gene but also a novel candidate for tumor suppression. Methylation-mediated inactivation of LRRC4, SIX3, and ANKDD1A has been verified as a frequent and glioblastoma-specific |
| **Gene Ontology Analysis** | **Promoter Hypomethylation Genes** |
| Cell communication and intracellular signal transduction | 14 Genes: ABR, OR1L6, FKB8, DRD4, SORBS1, GP1BB, OR10G4, BAD, C9, OR51S1, CCRL2, OR8A1, SFN, MLNR |
| Protein metabolic, cellular metabolic, and biopolymer metabolic process | 11 Genes: CPEB1, C9, FKB8, TUBB4Q, PRSS33, FUT5, NRBP2, PSMF1, OR51S1, KLHL21, TUBB8 |
| Transport including metal ion transport and cation transport, ion channel activity | 10 Genes: ACCN1, ABC12, SLC5A9, SLC2A9, KCNK4, TUBB4Q, TUBB8, MFS5D3, SLC28A1, SORBS1 |
| Hydrolase activity and serine hydrolase activity | 5 Genes: ABC12, OR51S1, TUBB4Q, TUBB8, PRSS33 |
| Regulation of gene expression, transcription, DNA binding, and transcription factor activity | 5 Genes: CPEB1, LMO3, PHF13, TOX2, NAT14 |
| Nervous system and organ development, and system development | 3 Genes: ACCN1, ABR, IGSF8 |
| Cell death, apoptotic program, and induction of apoptosis | 3 Genes: BAD, C9, SFN |
| **KEGG Pathway Analysis** | **Promoter Hypomethylation Genes** |
| Neuroactive ligand–receptor interaction | 3 Genes: SCT, DRD4, MLNR |
| Insulin signaling pathway | 2 Genes: BAD, SORBS1 |
event (15). SIX3 is a novel negative transcriptional regulator and acts as a tumor suppressor that directly represses the transcription of AURKA and AURKB in glioblastoma (26). ANKDD1A inhibits the transcriptional activity of HIF1α to alter hypoxia microenvironment by directly interacting with FIH1. The tumor-specific methylation of ANKDD1A indicates that it could be used as a potential epigenetic biomarker and also as a possible therapeutic target for glioblastoma.

**SIX NEW HYPMETHYLATION GENES IN GLIOBLASTOMA**

Signalmap software was used to select the following 12 genes from the 74 hypomethylated regions screened with the methylation chip: F10, POTEH, CPEB1, LMO3, ELFN2, PRDM16, CD207, BAD, NRBP2, SLITRK5, SLC44A2, and PGP. These genes were tested in a large scale of samples by BSP, which revealed that there is no difference between the methylation levels of CD207, BAD, NRBP2, SLITRK5, SLC44A2, and PGP in glioblastoma tissues and in normal brain tissues. F10 (27), POTEH (28), CPEB1 (29), LMO3 (30), ELFN2, and PRDM16 (31) were hypomethylated in glioblastoma tissues. They were confirmed to be novel hypomethylated genes in glioblastoma. Because of their higher expression, and poor outcomes in patients harboring these genes, these hypomethylated genes could be
Li P and Wu M

regarded as important prognostic markers of glioblastoma. While hypomethylation of F10 was correlated to patients' age, high expression of POTEH and hypomethylation of PRDM16 were related to astrocytoma pathology grade (Table 3). Thus, high expression of POTEH and hypomethylation of PRDM16 could be considered as important markers in the progression of glioblastoma. The glioblastoma tissues with a high POTEH expression level or PRDM16 hypomethylation would be more malignant than those with a low POTEH expression level or PRDM16 hypermethylation.

Figure 2 MassARRAY methylation analysis for glioblastoma. (A) MeDIP-chip assay detected hypermethylation genes' promoter methylation levels. Mass ARRAY assay were carried out using patients' samples gDNA screened by microarray. The position of CpG dinucleotides were marked by circles within the sequence (straight line), and the methylation levels were marked by different circle colors. Gray circles represent CpG sites that could not be analyzed. The base-pair position in the gene sequence used the ruler on top and CpG sites number at the bottom. In all tested genes, glioma samples have significant hypermethylation in promoter regions compared with normal controls. N1, N2, N3, and N5 represent normal brain, while T1, T2, T3, T4, T5, and T6 represent glioma samples. Glioma samples and normal samples were matched for age and sex. (B) Methylation levels of eight selected genes were identified by MeDIP-chip in glioma patients, normal controls, and glioma cell lines. DNA methylation was analyzed using MassARRAY assay. The gene names were marked in the top of each graph. N represents the number of cases for this research. In the top of each graph, the results of an individual gene are represented (20).
| Variables  | hypomethylation | Sex | Age(years) | Grade |
|------------|-----------------|-----|------------|-------|
|            | +               | −   | Male       | Female| <median | ≥median | Low grade (I+II) | High grade (III+IV) |
| FX(score)  |                 |     |            |       |         |         |                |                    |
| <8         | 12              | 9   | 9          | 12    | 12      | 9       | 10             | 11                 |
| ≥8         | 67              | 8   | 45         | 30    | 32      | 43      | 46             | 29                 |
| P          | 0.001           | 0.162 | 0.239     | 0.126 |         |         |                |                    |
| POTEH(score)|                 |     |            |       |         |         |                |                    |
| <8         | 27              | 12  | 23         | 16    | 15      | 24      | 29             | 10                 |
| ≥8         | 51              | 6   | 31         | 26    | 29      | 28      | 27             | 30                 |
| P          | 0.006           | 0.656 | 0.230     | 0.008 |         |         |                |                    |
| CPEB1(score)|                 |     |            |       |         |         |                |                    |
| <8         | 18              | 7   | 17         | 8     | 14      | 11      | 14             | 11                 |
| ≥8         | 25              | 0   | 17         | 8     | 9       | 16      | 12             | 13                 |
| P          | 0.010           | 1.000 | 0.781     | 0.571 |         |         |                |                    |
| LMO3(score) |                 |     |            |       |         |         |                |                    |
| <8         | 9               | 4   | 10         | 3     | 8       | 5       | 8              | 5                  |
| ≥8         | 34              | 3   | 24         | 13    | 19      | 18      | 18             | 19                 |
| P          | 0.043           | 0.508 | 0.526     | 0.424 |         |         |                |                    |
| ELFN2(score)|                 |     |            |       |         |         |                |                    |
| <8         | 12              | 6   | 11         | 7     | 9       | 9       | 10             | 8                  |
| ≥8         | 29              | 3   | 23         | 9     | 18      | 14      | 16             | 16                 |
| P          | 0.034           | 0.434 | 0.670     | 0.706 |         |         |                |                    |
| PRDM16(score)|                 |     |            |       |         |         |                |                    |
| <8         | 7               | 4   | 8          | 3     | 7       | 4       | 7              | 4                  |
| ≥8         | 36              | 3   | 26         | 13    | 20      | 19      | 19             | 20                 |
| P          | 0.016           | 0.704 | 0.468     | 0.382 |         |         |                |                    |

Note: Immunohistochemistry score ≥8 represents the high expression; <8 represents the low expression. The high expression of FX, POTEH, CPEB1, ELFN2, LMO3, and PRDM16 were companied by their hypomethylation in glioblastoma. And the hypomethylation of POTEH, CPEB1, LMO3, and ELFN2 did not have statistically significant correlation with sex, age, or histological grades. The hypomethylation of F10 was correlated to patients' ages, and high expression of POTEH and hypomethylation of PRDM16 were related to the pathology grade of astrocytoma.
miRNA and Methylation Genes in Glioblastoma

Epigenetic modifications encompass DNA methylation, chromatin remodeling, noncoding RNA expression, and histone tail modifications. Methylation modification is important for a proper genome function by maintaining chromatin structure, chromosome stability, and transcription. Histones are the protein moiety around chromatin, which is packaged by DNA, and their N-terminal tails can suffer a variety of post-translational modifications, such as methylation, acetylation, sumoylation, ubiquitination, phosphorylation, and ADP ribosylation (32, 33). MicroRNAs (miRNAs) are 20–22 nucleotide (nt) noncoding RNAs that bind to the 3' untranslated region of the target mRNA to form RNA-induced silencing complexes, which lead to the down regulation of genes by causing mRNA destabilization and/or translational inhibition (34, 35). miRNAs, as both targets and effectors, play a critical role in regulation of DNA methylation (36–39). Moreover, miRNAs can regulate DNA methylation by targeting the DNA methylation machinery.

THE LRRC4-AP-2-miR-182 LOOP

As miR-381 and miR-182 could facilitate glioblastoma cell growth in vitro and in vivo, they are regarded as potential therapeutic biomarkers in glioblastoma (40). The downregulation of miR-381 or miR-182 arrested cell cycle of glioblastoma cells in the G0/G1 phase and inhibited their proliferation by suppressing E2F3 and upregulating phosphorylated Rb. LRRC4 was the co-target gene of miR-381 and miR-182, and its expression was inversely correlated with miR-381, miR-182, and BRD7 in glioblastoma. Knockdown of miR-182 and miR-381 inhibited LRRC4-mediated binding of AP-2/SP1/E2F6/c-Myc to BRD7 by ERK/MAPK and PI-3K/AKT (40). Transcription of miR-182 was induced by the transcription factor AP-2, as predicted by online software and confirmed by ChIP. miR-182 inhibited the expression of LRRC4, and LRRC4 inhibited the expression and transcription of AP-2 by negatively regulating the ERK/MAPK and PI-3K/AKT signaling pathways. This indicated that the LRRC4-AP-2-miR-182-LRRC4 loop is involved in glioblastoma development (40).

THE LRRC4-miR-185/SP1-DNMT1 LOOP

LRRC4 upregulation induced the expression of miR-185, and the LRRC4-miR-185/SP1-DNMT1-LRRC4 loop played a key role in glioblastoma: miR-185 inhibited cell motility, invasion, and proliferation; and DNMT1, one of the most important DNA methyltransferases, maintained methylation. miR-185 upregulation inhibited DNMT1 and decreased global methylation through HPLC-DAD; it also downregulated the expression of nine novel hypermethylated genes (SIX3, SST, LRRC4, GAD1, PCDHA8, PHOX2B, PCDHA13, ANKDD1A, and HIST1H3E) (20). Thus, miR-185 acts as a tumor suppressor by targeting DNMT1 to decrease global methylation and recover hypermethylation of these genes. The GO methodology is a success-oriented probabilistic system performance analysis technique. Based on GO methodology, miR-185 was also considered to be involved in Rho GTPase activity. RhoA and CDC42 were the direct targets of miR-185, and
the expression of these two molecules was negatively correlated with miR-185 in glioblastoma. Overexpression of miR-185 reduced the growth and migration of glioblastoma cells by inhibiting RhoA, CDC42 directly, and VEGFA indirectly (20). In summary, LRRC4 could regulate miRNAs as a tumor suppressor gene. These processes constitute multiple circuits, including LRRC4-miR-185-DNMT1-LRRC4, LRRC4-SP1-DNMT1-LRRC4, and LRRC4-AP-2-miR-182-LRRC4. These circuits take part in the development of glioblastoma with multiple feedback mechanisms (Figure 3).

**Figure 3** The regulation networks of hypermethylated genes, miRNA, DNMT, transcript factors, and target genes in glioblastoma. LRRC4-AP-2-miR-182-LRRC4 loop: LRRC4 is a common target of miR-182 and miR-381, and miR-182 and miR-381 inhibit LRRC4 expression; meanwhile, the re-expression of LRRC4 also decreases miR-182 and miR-381 expression. The transcription of miR-182 is induced by AP-2; however, LRRC4 also inhibits the expression of AP-2 through negatively regulating the ERK/MAPK and PI-3K/AKT signaling pathways. The LRRC4-AP-2-miR-182-LRRC4 loop was formed among LRRC4, miR-182, and AP-2. LRRC4-miR-185-DNMT1-LRRC4 loop: The re-expression of LRRC4 increases miR-185 expression, while miR-185 decreases global methylation by targeting DNMT1 and increases the expression of LRRC4. LRRC4-SP1-DNMT1-LRRC4 loop: DNMT1 is positively regulated by SP1, and it increases the expression of LRRC4, while LRRC4 also inhibits SP1 by negatively regulating the ERK/MAPK and PI-3K/AKT signal pathway (Adapted from Mol Cancer 2011;10:124.)
miR-101 AND HYPOMETHYLATION GENES

It has been shown that miR-101 is downregulated in multiple tumors, including glioblastoma, and acts as a tumor suppressor. Interestingly, the novel hypomethylation genes CPEB1, PRDM16, ELFN2, and LMO3 were predicted to be targeted by miR-101. CPEB1, PRDM16, and ELFN2 were verified to be the direct target genes of miR-101; however, LMO3 was not the direct target (Figure 4). miR-101 suppressed CPEB1 expression by reversing the CPEB1 promoter methylation status. Furthermore, miR-101 reversed CPEB1 promoter methylation status by regulating the methylation-related histones H3K27me3, H3K4me2, H4K20me3, and H3K9me3. In addition, the decreased expression of CPEB1 triggered senescence in a p53-dependent manner (Figure 4). miR-101 downregulated LMO3 expression by reversing the LMO3 promoter methylation status, inhibiting the presence of the methylation-related histones H3K27me3 and H3K4me2, and increasing the presence of H4K20me3 and H3K9me3 on the promoter. miR-101 reduced the occupancy of H3K27me3 through suppressing EED, DNMT3A, and EZH2, and reduced the H3K9me3 occupancy on the LMO3 promoter by PHF8, G9a, SUV39H1, and SUV39H2. Moreover, miR-101 inhibited LMO3 expression by reducing MZF1 and USF (Figure 4). miR-101 also reduced PRDM16 expression by affecting the PRDM16 promoter methylation status. miR-101 was related to an increase in H4K20me3 and H3K9me3 and a decrease in the methylation-related histones H3K27me3 and H3K4me2 on the PRDM16 promoter. In addition, miR-101 suppressed PRDM16 expression by targeting DNMT3A, which decreased histones H3K27me3 and H3K4me2 at the PRDM16 core promoter (Figure 4). In addition, miR-101 also reduced H3K27me3 occupancy at the core promoter of the hypermethylation gene LRRC4 and reversed the LRRC4 methylation level through targeting EED, EZH2, and DNMT3A (Figure 4).

LncRNA, miRNA, and Methylation in Glioblastoma

INTERACTION OF LNCRNA AND miRNA

LncRNAs regulate gene transcription (41), chromatin remodeling (42), post-transcriptional processing of mRNA (43), and competing endogenous RNA (ceRNA) (44, 45). Emerging evidence suggests that LncRNAs communicate with ncRNAs, mRNAs, proteins, and genomic DNA, and act as tethers, guides, decoys, and scaffolds (46, 47). LncRNAs can participate in the ceRNA regulatory network and act as endogenous miRNA sponges to compete for binding of miRNA through MRE, which is “the letters” of the RNAcode (48). ceRNAs and miRNAs repress reciprocally and form a double-negative feedback loop (49, 50). Online promoterInspector and promoterScan softwares predicted that the CpG island status on the promoter of pre-miR-101-1 and pre-miR-101-2 is not the reason for the lower expression of miR-101. Furthermore, the LOH in chromosomes 1p31(pre-miR-101-1) and 9p24 (pre-miR-101-2) was insufficient to lower the expression of miR-101 in glioblastoma. The software programs DIANA LAB and miRanda were used to search for LncRNAs and there were 18 LncRNAs predicted to form putative binding sites with miR-101. However, only six LncRNAs have been confirmed to
Figure 4 The networks of miRNA, gene methylation, and histone modification in glioblastoma.
The hypomethylated genes CPEB1, PRDM16, and ELFN2 are target genes of miR-101, but LMO3 is not, and the expression of CPEB1, PRDM16, and ELFN2 are inhibited directly by miR-101. Moreover, miR-101 also indirectly suppresses the expression of CPEB1, ELFN2, PRDM16, and LMO3 and affects their methylation levels by targeting EZH2, EED, and DNMT3A and regulating histone methylation; miR-101 decreases the occupancy of H3K4me2 and H3K27me3 at CPEB1, ELFN2, PRDM16, and LMO3 core promoter and increases the H3K9me3 and H4K20me3 occupancy at CPEB1, PRDM16, and LMO3 gene promoter, and indirectly downregulates the expression of these hypomethylation genes. miR-101 does not bind to 3'UTR of hypermethylated gene LRRC4, but it remains to upregulate the expression of LRRC4. miR-101 decreases the occupancy of H3K27me3 at LRRC4 core promoter and induces hypomethylation of LRRC4 by targeting EZH2, EED, and DNMT3A. In short, miRNAs can not only directly regulate expression of hyper-/hypomethylation genes by binding to 3'-UTR of genes but also regulate the methylation level and gene expression through histone and DNA methylation modification by targeting histone and DNA methyltransferases (Xiaoping Liu. Doctor's thesis. Central South University, 2012).
show significantly different expression between glioblastoma and normal brain tissues. CASC2c was bound to miR-101 directly by MRE of miR-101, and there was a reciprocal repression between CASC2c and miR-101. The higher expression of CASC2c is one of the reasons for the low expression of miR-101. CASC2c is also the target of miR-101 and commonly exists in the RISC complex with miR-101. A high level of CASC2c positively regulated the expression of pre-miR-101; however, in the processing from pre-miR-101 to mature miR-101, CASC2c negatively regulated the expression of Dicer and inhibited the expression of mature miR-101 in glioblastoma (51). CASC2c is a long noncoding RNA and provided evidence that high expression of CASC2c occurred in glioblastoma. Knockdown CASC2c suppressed the proliferation, migration, and invasion in vitro and glioblastoma tumorigenesis in vivo.

EFFECT OF LncRNA ON METHYLATION GENES IN GliOBLASTOMA

CASC2c functions as a suppressor of miR-101 or as a competitor of its target genes such as CPEB1, PRDM16, and LMO3. The expression of hypomethylation genes CPEB1, PRDM16, and LMO3 was increased in glioblastoma, and the depletion of CASC2c led to their repression. Thus, in normal tissue, CASC2c, miR-101, and target genes keep a balance by competitive restriction. In glioblastoma, because of the high expression of CASC2c; low expression of miR-101; or the overexpression of CPEB1, PRDM16, and LMO3 as a result of hypomethylation status of its promoter, the balance of this regulatory feedback is lost. In terms of complexity of molecular mechanisms in tumors, a cause-and-effect relationship among CASC2c, miR-101, CPEB1, PRDM16, and LMO3 could not be established. Despite this, miR-101 might be a core unit, and MRE of miR-101 is important for the crosstalk among CASC2c, miR-101, and their target genes in glioblastoma.

Conclusion

The application of next-generation sequencing enabled DNA methylation and its derivatives, 5fC and 5hmC, to be mapped at base-pair resolution. These studies have offered novel viewpoints into the distribution, dynamics, and function of DNA methylation in vertebrate genomes. Focal DMRs and DM site studies will be helpful for the discovery of regulatory elements of transcription factors, which may participate in specific gene regulation in vivo. Model systems should be used to test the functionality of individual DM sites or DMRs identified in epigenomic profiles. In the near future, studies of intragenic and distant intergenic alterations in DNA methylation will help elucidate the nature of epigenetic deregulation in diseases, especially for glioblastoma.

Acknowledgment: This study was supported by grants from the National Science Foundation of China (81272297), National Key Technology Research and Development program of the Ministry of Science and Technology of China (2014BAI04B02), and Hunan Province Natural Sciences Foundations (2015JJ2167).
Conflict of interest: The authors declare no potential conflicts of interest with respect to research, authorship, and/or publication of this manuscript.

Copyright and permission statement: To the best of our knowledge, the materials included in this chapter do not violate copyright laws. All original sources have been appropriately acknowledged and/or referenced. Where relevant, appropriate permissions have been obtained from the original copyright holders.

References

1. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007 Feb 23;128(4):683–92. http://dx.doi.org/10.1016/j.cell.2007.01.029
2. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet. 2001 Apr;10(7):687–92. http://dx.doi.org/10.1093/hmg/10.7.687
3. Laird PW. Cancer epigenetics. Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R65–76. http://dx.doi.org/10.1093/hmg/ddi113
4. Ehrlich M. DNA methylation in cancer: Too much, but also too little. Oncogene. 2002 Aug 12;21(35):5400–13. http://dx.doi.org/10.1038/sj.onc.1205651
5. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003 Nov 20;349(21):2042–54. http://dx.doi.org/10.1056/NEJMoa023075
6. Kim TY, Zhong S, Fields CR, Kim JH, Robertson KD. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res. 2006 Aug 1;66(15):7490–501. http://dx.doi.org/10.1158/0008-5472.CAN-05-4552
7. Komine C, Watanabe T, Katayama Y, Yoshino A, Yokoyama T, Fukushima T. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol. 2003 Apr;13(2):176–84. http://dx.doi.org/10.1111/j.1750-3639.2003.tb00017.x
8. Yin D, Xie D, Hofmann WK, Zhang W, Asotra K, Wong R, et al. DNA repair gene O6-methylguanine-DNA methyltransferase: Promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors. Mol Carcinog. 2003 Jan;36(1):23–31. http://dx.doi.org/10.1002/mc.10094
9. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004 Mar 15;10(6):1871–4. http://dx.doi.org/10.1158/1078-0432.CCR-03-0384
10. Ohta T, Watanabe T, Katayama Y, Yoshino A, Yachi K, Ogino A, et al. Aberrant promoter hypermethylation profile of cell cycle regulatory genes in malignant astrocytomas. Oncol Rep. 2006 Nov;16(5):957–63. http://dx.doi.org/10.3892/or.16.5.957
11. Amatya VJ, Naumann U, Weller M, Ohgaki H. TP53 promoter methylation in human gliomas. Acta Neuropathol. 2005 Aug;110(2):178–84. http://dx.doi.org/10.1007/s00401-005-1041-5
12. Hesson L, Beiche I, Krex D, Crimere E, Hoang-Xuan K, Maher ER, et al. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene. 2004 Mar 25;23(13):2408–19. http://dx.doi.org/10.1038/sj.onc.1207407
13. Horiguchi K, Tomizawa Y, Tosaka M, Ishiuchi S, Kurihara H, Mori M, et al. Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors. Oncogene. 2003 Oct 30;22(49):7862–5. http://dx.doi.org/10.1038/sj.onc.1207082
14. Wiencke JK, Zheng S, Jelluma N, Tihan T, Vandenberg S, Tamgüney T, et al. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol. 2007 Jul;9(3):271–9. http://dx.doi.org/10.1215/15228517-2007-003
15. Zhang Z, Li D, Wu M, Xiang B, Wang L, Zhou M, et al. Promoter hypermethylation-mediated inactivation of LRRC4 in gliomas. BMC Mol Biol. 2008 Nov 3;9:99. http://dx.doi.org/10.1186/1471-2199-9-99

16. Fukushima T, Katayama Y, Watanabe T, Yoshino A, Ogino A, Ohta T, et al. Promoter hypermethylation of mismatch repair gene hMLH1 predicts the clinical response of malignant astrocytomas to nitrosourea. Clin Cancer Res. 2005 Feb 15;11(4):1539–44. http://dx.doi.org/10.1158/1078-0432.CCR-04-1625

17. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis. 2001 Oct;22(10):1715–19. http://dx.doi.org/10.1093/carcin/22.10.1715

18. Waha A, Gunter S, Huang TH, Yan PS, Arslan B, Pietsch T, et al. Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas. Neoplasia. 2005 Mar;7(3):193–9. http://dx.doi.org/10.1593/neo.04490

19. Stone AR, Bobo W, Brat DJ, Devi NS, Van Meir EG, Vertino PM. Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am J Pathol. 2004 Oct;165(4):1151–61. http://dx.doi.org/10.1016/S0002-9440(10)63376-7

20. Zhang Z, Tang H, Wang Z, Zhang B, Liu W, Lu H, et al. Mir-185 targets the DNA methyltransferases 1 and regulates global DNA methylation in human glioma. Mol Cancer. 2011 Sep 30;10:124. http://dx.doi.org/10.1186/1476-4598-10-124

21. Riemenschneider MJ, Reifenberger J, Reifenberger G. Frequent biallelic inactivation and transcriptional silencing of the DIRAS3 gene at 1p31 in oligodendroglional tumors with 1p loss. Int J Cancer. 2008 Jun 1;122(11):2503–10. http://dx.doi.org/10.1002/ijc.23409

22. Yates DR, Rehman I, Abbod MF, Meuth M, Cross SS, Linkens DA, et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res. 2007 Apr 1;13(7):2046–53. http://dx.doi.org/10.1158/1078-0432.CCR-06-2476

23. Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D, et al. CpG island hypermethylation in human astrocytomas. Cancer Res. 2010 Apr 1;70(7):2718–27. http://dx.doi.org/10.1158/0008-5472.CAN-09-3631

24. Huang KH, Huang SF, Chen IH, Liao CT, Wang HM, Hsieh LL. Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma. Clin Cancer Res. 2009 Jun 15;15(12):4174–80. http://dx.doi.org/10.1158/1078-0432.CCR-08-2929

25. Huang J, Lin Y, Li LH, Qing D, Teng XM, Zhang YL, et al. ARHI, As a novel suppressor of cell growth and downregulated in human hepatocellular carcinoma, could contribute to hepatocarcinogenesis. Mol Carcinog. 2009 Feb;48(2):130–40. http://dx.doi.org/10.1002/mc.20461

26. Yu Z, Sun Y, She X, Wang Z, Chen S, Deng Z, et al. SIX3, a tumor suppressor, inhibits astrotoma tumorigenesis by transcriptional repression of AURKA/B. J Hematol Oncol. 2017 Jun 8;10(1):115. http://dx.doi.org/10.1186/s13045-017-0483-2

27. Liu X, Tang H, Wang Z, Huang C, Zhang Z, She X, et al. F10 gene hypomethylation, a putative biomarker for glioma prognosis. J Neurooncol. 2012 May;107(3):479–85. http://dx.doi.org/10.1007/s11060-011-0775-2

28. Liu X, Tang H, Zhang Z, Li W, Wang Z, Zheng Y, et al. POTEH hypomethylation, a new epigenetic biomarker for glioma prognosis. Brain Res. 2011 May 19;1391:125–31. http://dx.doi.org/10.1016/j.brainres.2011.03.042

29. Liu X, Yu Z, Li W, Wang Z, Xu G, Li ZH, et al. CPEB1, a histone-modified hypomethylated gene, is regulated by miR-101 and involved in cell senescence in glioma. Cell Death Dis. 2013 Jun 20;4:e675. http://dx.doi.org/10.1038/cddis.2013.197

30. Liu X, Lei Q, Yu Z, Xu G, Tang H, Wang W, et al. LMO3 MiR-101 reverses the hypomethylation of the LMO3 promoter in glioma cells. Oncotarget. 2015 Apr 10;6(10):7930–43. http://dx.doi.org/10.18632/oncotarget.3181

31. Lei Q, Liu X, Fu H, Sun Y, Wang L, Xu G, et al. miR-101 reverses hypomethylation of the PRDM16 promoter to disrupt mitochondrial function in astrocytoma cells. Oncotarget. 2016 Jan 26;7(4):5007–22.
32. Bhaumik SR, Smith E, Shilatifard A. Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol. 2007 Nov;14(11):1008–16. http://dx.doi.org/10.1038/nsmb1337
33. Kouzarides T. Chromatin modifications and their function. Cell. 2007 Feb 23;128(4):693–705. http://dx.doi.org/10.1016/j.cell.2007.02.005
34. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004 Jan 23;116(2):281–97. http://dx.doi.org/10.1016/s0092-8674(04)00045-5
35. He L, Hannon GJ. Micrornas: Small RNAs with a big role in gene regulation. Nat Rev Genet. 2004 Jul;5(7):522–31. http://dx.doi.org/10.1038/nrg1379
36. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene bcl6 by chromatin-modifying drugs in human cancer cells. Cancer Cell. 2006 Jun;9(6):435–43. http://dx.doi.org/10.1016/j.ccr.2006.04.020
37. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3a and 3b. Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15805–10. http://dx.doi.org/10.1073/pnas.0707628104
38. Benetritti R, Gonzalez S, Iaco M, Munoz P, Gonzalez S, Schoeftner S, et al. A mammalian microRNA cluster controls DNA methylation and telomere recombination via rbl2-dependent regulation of DNA methyltransferases. Nat Struct Mol Biol. 2008 Sep;15(9):998. http://dx.doi.org/10.1038/nsmb0908-998b
39. Wu L, Zhou H, Zhang Q, Zhang J, Ni F, Liu C, et al. DNA methylation mediated by a microRNA pathway. Mol Cell. 2010 May 14;38(3):465–75. http://dx.doi.org/10.1016/j.molcel.2010.03.008
40. Tang H, Liu X, Wang Z, She X, Zeng X, Deng M, et al. Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth. Brain Res. 2011 May 16;1390:21–32. http://dx.doi.org/10.1016/j.brainres.2011.03.034
41. Goodrich JA, Kugel JF. Non-coding-RNA regulators of RNA polymerase II transcription. Nat Rev Mol Cell Biol. 2006 Aug;7(8):612–16. http://dx.doi.org/10.1038/nrm1946
42. Kanduri C. Kcnq1ot1: A chromatin regulatory RNA. Semin Cell Dev Biol. 2011 Jun;22(4):343–50. http://dx.doi.org/10.1016/j.semcdb.2011.02.020
43. Wang K, Sun T, Li N, Wang Y, Wang JX, Zhou LY, et al. MDRL IncRNA regulates the processing of miR-484 primary transcript by targeting miR-361. PLoS Genet. 2014 Jul 24;10(7):e1004467. http://dx.doi.org/10.1371/journal.pgen.1004467
44. Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 2011 Oct 14;147(2):358–69. http://dx.doi.org/10.1016/j.cell.2011.09.028
45. Fan M, Li X, Jiang W, Huang Y, Li J, Wang Z. A long non-coding RNA, PTCSC3, as a tumor suppressor and a target of miRNAs in thyroid cancer cells. Exp Ther Med. 2013 Apr;5(4):1143–6.
46. Yan B, Yao J, Liu JY, Li XM, Wang XQ, Li YJ, et al. LncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. Circ Res. 2015 Mar 27;116(7):1143–56. http://dx.doi.org/10.1161/CIRCRESAHA.116.305510
47. Ebert MS, Sharp PA. Emerging roles for natural microRNA sponges. Curr Biol. 2010 Oct 12;20(19):R858–61. http://dx.doi.org/10.1016/j.cub.2010.08.052
48. Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer A, Llobet-Navas D, et al. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell. 2011 Oct 14;147(2):370–81. http://dx.doi.org/10.1016/j.cell.2011.09.041
49. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfo P. A ceRNA hypothesis: The Rosetta Stone of a hidden RNA language? Cell. 2011 Aug 5;146(3):353–8. http://dx.doi.org/10.1016/j.cell.2011.07.014
50. Yan L, Zhou J, Gao Y, Ghazal S, Lu L, Bellone S, et al. Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation. Oncogene. 2015 Jun 4;34(23):3076–84. http://dx.doi.org/10.1038/onc.2014.236
51. Liu C, Sun Y, She X, Tu C, Cheng X, Wang L, et al. CASC2c as an unfavorable prognosis factor interacts with miR-101 to mediate astrocytoma tumorigenesis. Cell Death Dis. 2017 Mar 2;8(3):e2639. http://dx.doi.org/10.1038/cddis.2017.11